| HOME >> BIOLOGY >> TECHNOLOGY |
2008 2007
Expectations Results % Growth
---------------- ------- ----------
E.P.S. (reported) $3.90 to $4.05 $2.71 44% to 49%
Benefit from resolution of IRS audit (.19) -
Asset impairments and restructuring
charges .09 .15
Charge for a reduction in expected
insurance recoveries - .06
In-process research & development
charges associated with BioMS
Medical in-licensing (2008) and
ICOS, Hypnion, and Ivy acquisitions
and OSI, MacroGenics and Glenmark
in-licensings (2007) .05 .63
Pro forma as if the ICOS
acquisition was completed on
January 1, 2007 - (.01)
---------------- ------- ----------
Totals $3.85 to $4.00 $3.54 9% to 13%
---------------- ------- ----------
Webcast of Conference Call
As previously announced, investors and the general public can access a live webcast of the first-quarter 2008 financial results conference call through a link on Lilly's website at http://www.lilly.com. The conference call will be held today from 8:00 a.m. to 9:00 a.m. Eastern Daylight Time (EDT) and will be available for replay via the website through May 23, 2008.
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific
'/>"/>
| SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved |